| Page 108 | Kisaco Research

Grant funding can be a catalyst for scientific and commercial progress. Adriann Sax, CEO & Co-Founder of Vetigenics, shares how strategic use of SBIR and foundation grants enabled the company to build a canine antibody platform, attract support from investors, and secure partners such as Merck Animal Health.

Funding
Grant
Canine
Milestone - Platform Technology
Antibody

Author:

Adriann Sax

President & CEO
Vetigenics

Adriann Sax

President & CEO
Vetigenics

Machine learning is reshaping discovery science in Human Health and Organicin Scientific is proving its potential in animal health too. Mat Mitchell, Co-Founder and CTO, shares how Organicin Scientific’s machine-learning platform automates candidate selection to identify, evaluate, and commercialise novel antimicrobials for safe and sustainable use across the industry.

Machine Learning
R&D
Drug Discovery
Antimicrobial
AI

Author:

Mathew Mitchell

Co-Founder and CTO
Organicin Scientific

Mathew Mitchell

Co-Founder and CTO
Organicin Scientific

With resistance to existing parasiticides rising and few new molecules in decades, ASTRA Therapeutics set out to change the game. Co-CEOs Natacha Gaillard and Ashwani Sharma share how the company closed one of the largest seed rounds in animal health, positioned itself to deliver precision-designed antiparasitics, and built investor confidence in solving one of animal health’s most urgent challenges.

Milestone - Funding
Parasiticides
Investment
Seed Funding
Biopharma
Companion and Livestock

Author:

Natacha Gaillard

Co-Founder and Co-CEO
ASTRA Therapeutics

Natacha Gaillard

Co-Founder and Co-CEO
ASTRA Therapeutics

Author:

Ashwani Sharma

Co-Founder and Co-CEO
ASTRA Therapeutics

Ashwani Sharma

Co-Founder and Co-CEO
ASTRA Therapeutics